I agree that this site is using cookies. You can find further informations here.
X
Cotte, François-Emery
227  results:
Search for persons X
?
1

A Cost-Effectiveness Analysis of Adjuvant Nivolumab for Pat..:

Casabianca, Paul ; Massetti, Marc ; Cotte, François-Emery...
PharmacoEconomics - Open.  , 2024
Link: https://doi.org/10.1007/..
 
?
2

Characteristics, management, and healthcare resources of pa..:

Assié, Jean-Baptiste ; Grumberg, Valentine ; Reynaud, Dorothée...
Respiratory Medicine and Research.  84 (2023)  - p. 101051 , 2023
Link: https://doi.org/10.1016/..
 
?
3

Cost-effectiveness of idecabtagene vicleucel compared with ..:

Karampampa, Korinna ; Zhang, Wenjie ; Venkatachalam, Meena..
Journal of Medical Economics.  26 (2023)  1 - p. 243-253 , 2023
Link: https://doi.org/10.1080/..
 
?
4

Outcome following nivolumab treatment in patients with adva..:

Assié, Jean-Baptiste ; Chouaïd, Christos ; Nunes, Hilario...
Therapeutic Advances in Medical Oncology.  15 (2023)  - p. 175883592311528 , 2023
Link: https://doi.org/10.1177/..
 
?
5

Apixaban versus other anticoagulants in patients with nonva..:

Belhassen, Manon ; Hanon, Olivier ; Steg, Philippe Gabriel...
The European Journal of Health Economics.  24 (2022)  6 - p. 867-875 , 2022
Link: https://doi.org/10.1007/..
 
?
6

Long-term hospital resource utilization and associated cost..:

Grumberg, Valentine ; Chouaïd, Christos ; Cotté, François-Emery...
Journal of Medical Economics.  25 (2022)  1 - p. 691-699 , 2022
Link: https://doi.org/10.1080/..
 
?
7

Comparative non-persistence in the first year of treatment ..:

Danchin, Nicolas ; Steg, Gabriel ; Mahé, Isabelle...
Archives of Cardiovascular Diseases.  115 (2022)  11 - p. 571-577 , 2022
Link: https://doi.org/10.1016/..
 
?
8

Effectiveness of Nivolumab in Second-Line and Later in Pati..:

Chouaid, Christos ; Thomas, Michael ; Debieuvre, Didier...
Cancers.  14 (2022)  24 - p. 6148 , 2022
Link: https://doi.org/10.3390/..
 
?
9

Impact of open-label versus blinded study design on patient..:

Anota, Amélie ; Pozet, Astrid ; Lemasson, Hervé...
Quality of Life Research.  31 (2021)  3 - p. 645-657 , 2021
Link: https://doi.org/10.1007/..
 
?
10

Effectiveness and safety of nivolumab in the treatment of l..:

Barlesi, Fabrice ; Dixmier, Adrien ; Debieuvre, Didier...
OncoImmunology.  9 (2020)  1 - p. , 2020
Link: https://doi.org/10.1080/..
 
?
11

Cost–Utility Analysis of Nivolumab in Adjuvant Treatment of..:

Bregman, Bruno ; Teitsson, Siguroli ; Orsini, Isabella...
Dermatology and Therapy.  10 (2020)  6 - p. 1331-1343 , 2020
Link: https://doi.org/10.1007/..
 
?
12

Immunotherapy rechallenge after nivolumab treatment in adva..:

Giaj Levra, Matteo ; Cotté, François-Emery ; Corre, Romain...
Lung Cancer.  140 (2020)  - p. 99-106 , 2020
Link: https://doi.org/10.1016/..
 
?
13

Nivolumab treatment in advanced non-small cell lung cancer:..:

Assié, Jean-Baptiste ; Corre, Romain ; Levra, Matteo Giaj...
Therapeutic Advances in Medical Oncology.  12 (2020)  - p. 175883592096723 , 2020
Link: https://doi.org/10.1177/..
 
?
14

Economic burden of chemotherapy-treated recurrent and/or me..:

Lafuma, Antoine ; Cotté, François-Emery ; Le Tourneau, Christophe...
Journal of Medical Economics.  22 (2019)  7 - p. 698-705 , 2019
Link: https://doi.org/10.1080/..
 
?
15

Access to innovative drugs for metastatic lung cancer treat..:

Scherpereel, Arnaud ; Durand-Zaleski, Isabelle ; Cotté, François-Emery...
BMC Cancer.  18 (2018)  1 - p. , 2018
Link: https://doi.org/10.1186/..
 
1-15